<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36890462</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Factors related to the mortality risk of severe hand, foot, and mouth diseases (HFMD): a 5-year hospital-based survey in Guangxi, Southern China.</ArticleTitle><Pagination><StartPage>144</StartPage><MedlinePgn>144</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">144</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-023-08109-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To understand the factors influencing clinical outcomes of severe hand, foot, and mouth diseases (HFMD), and to provide scientific evidence for reducing the mortality risk of severe HFMD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From 2014 to 2018, children diagnosed with severe HFMD cases in Guangxi, China, were enrolled in this hospital-based study. The epidemiological data obtained through face-to-face interviews with the parents and guardians. Univariate and multivariate logistics regression models were used to analyze the factors influencing the clinical outcomes of severe HFMD. The impact of the EV-A71 vaccination on inpatient mortality was analyzed by a comparison approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1565 severe HFMD cases were enrolled in this survey, including 1474 (94.19%) survival cases and 91 (5.81%) death cases. The multivariate logistic analysis demonstrated that HFMD history of playmates in the last three months, first visit to the village hospital, time from the first visit to admission less than two days, no correct diagnosis for HFMD at the first visit, and having no rash symptoms were the independent risk factors for severe HFMD cases (all p &lt; 0.05). While EV-A71 vaccination was a protective factor (p &lt; 0.05). The EV-A71 vaccination group versus the non-vaccination group showed 2.23% of death in the vaccination group and 7.24% of death in the non-vaccination group. The EV-A71 vaccination protected 70.80% of the death of severe HFMD cases, with an effective index of 4.79.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The mortality risk of severe HFMD in Guangxi was related to playmates had HFMD history in last 3 months, hospital grade, EV-A71 vaccination, patients visit hospital previously, and rash symptom. EV-A71 vaccination can significantly reduce mortality among severe HFMD. The findings are of great significance for the effective prevention and control of HFMD in Guangxi, southern China.</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Peng</LastName><ForeName>Yuanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>He</LastName><ForeName>Weitao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Acute Infectious Disease Prevention and Control, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Zhigang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, 530200, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Peijiang</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>China (Guangxi)-ASEAN Joint Laboratory of Emerging Infectious Diseases, Life Science Institute, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Acute Infectious Disease Prevention and Control, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zhenwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yanyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>China (Guangxi)-ASEAN Joint Laboratory of Emerging Infectious Diseases, Life Science Institute, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hailong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>China (Guangxi)-ASEAN Joint Laboratory of Emerging Infectious Diseases, Life Science Institute, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Acute Infectious Disease Prevention and Control, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Acute Infectious Disease Prevention and Control, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Acute Infectious Disease Prevention and Control, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>China (Guangxi)-ASEAN Joint Laboratory of Emerging Infectious Diseases, Life Science Institute, Guangxi Medical University, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Minmei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Acute Infectious Disease Prevention and Control, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530028, China. 13707719199@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi, China. yeli@gxmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>China (Guangxi)-ASEAN Joint Laboratory of Emerging Infectious Diseases, Life Science Institute, Guangxi Medical University, Nanning, 530021, Guangxi, China. yeli@gxmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2017GXNSFAA198369</GrantID><Agency>Guangxi Natural Science Foundation Programs</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005076" MajorTopicYN="Y">Exanthema</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009059" MajorTopicYN="Y">Mouth Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-A71 vaccination</Keyword><Keyword MajorTopicYN="N">Hand, foot and mouth disease</Keyword><Keyword MajorTopicYN="N">Influencing factors</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Severe cases</Keyword></KeywordList><CoiStatement>The authors have no competing/conflicting interests to declare in this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36890462</ArticleId><ArticleId IdType="pmc">PMC9993373</ArticleId><ArticleId IdType="doi">10.1186/s12879-023-08109-y</ArticleId><ArticleId IdType="pii">10.1186/s12879-023-08109-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang CC, Liu CC, Chang YC, Yeh TF, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341(13):936–942. doi: 10.1056/NEJM199909233411302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie YH, Chongsuvivatwong V, Tang Z, et al. Spatio-temporal clustering of hand, foot, and mouth disease at the county level in Guangxi, China. PLoS ONE. 2014;9(2):e88065. doi: 10.1371/journal.pone.0088065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0088065</ArticleId><ArticleId IdType="pmc">PMC3914922</ArticleId><ArticleId IdType="pubmed">24505378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Ju Y, Chen M, et al. Epidemiological and genetic characteristics of EV71 in hand, foot, and mouth disease in Guangxi, southern China, from 2010 to 2015. PLoS ONE. 2017;12(12):e0188640. doi: 10.1371/journal.pone.0188640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0188640</ArticleId><ArticleId IdType="pmc">PMC5720782</ArticleId><ArticleId IdType="pubmed">29216216</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin HY, Gau SS, et al. Enterovirus A71 neurologic complications and long-term sequelae. J Biomed Sci. 2019;26(1):57. doi: 10.1186/s12929-019-0552-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0552-7</ArticleId><ArticleId IdType="pmc">PMC6688366</ArticleId><ArticleId IdType="pubmed">31395054</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine. 2012;30(22):3295–3303. doi: 10.1016/j.vaccine.2012.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Xia JL, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. J Infect Dis. 2014;209(1):46–55. doi: 10.1093/infdis/jit429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Song YF, Wang L, et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15(1):129–137. doi: 10.1586/14760584.2016.1096782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1096782</ArticleId><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Jiang L, Zhang C, He W, Tan Y, Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39(25):3319–3323. doi: 10.1016/j.vaccine.2021.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.009</ArticleId><ArticleId IdType="pubmed">33994239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health of the People’s Republic of China. Guide of diagnosis and Treatment for Hand, Foot, Mouth disease (2010 version). http://yzs.satcm.gov.cn/gongzuodongtai/2018-03-24/3073.html.</Citation></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>The Ministry of Health of China. Guidelines for the Prevention and Control of Hand, Foot, and Mouth disease (2009 version). http://www.gov.cn/gzdt/2009-06/04/content_1332078.htm.</Citation></Reference><Reference><Citation>The Ministry of Health of China. Guidelines for the Prevention and Control of Hand, Foot, and Mouth disease (2008 version).http://www.gov.cn/yjgl/2008-05/03/content_960347.htm.</Citation></Reference><Reference><Citation>Peng D, Ma Y, Liu Y, Lv Q, Yin F. Epidemiological and aetiological characteristics of hand, foot, and mouth disease in Sichuan Province, China, 2011–2017. Sci Rep. 2020;10(1):6117. doi: 10.1038/s41598-020-63274-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-63274-3</ArticleId><ArticleId IdType="pmc">PMC7145801</ArticleId><ArticleId IdType="pubmed">32273569</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Zhang G, Guo P, et al. Epidemiological characterizations, pathogen spectrum and molecular characteristics of Coxsackievirus A16 from patients with HFMD in Yantai, Shandong, China between 2011 and 2015. Hum Vaccin Immunother. 2017;13(8):1831–1838. doi: 10.1080/21645515.2017.1318233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1318233</ArticleId><ArticleId IdType="pmc">PMC5557242</ArticleId><ArticleId IdType="pubmed">28537484</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liao Q, Ooi MH, et al. Epidemiology of recurrent hand, foot and mouth disease, China, 2008–2015. Emerg Infect Dis. 2018;24(3):432–442. doi: 10.3201/eid2403.171303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2403.171303</ArticleId><ArticleId IdType="pmc">PMC5823341</ArticleId><ArticleId IdType="pubmed">29460747</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosazadeh M, Abedi G, Afshari M, Kheradmand E, et al. Prevalence of enterobius vermicularis among children in Iran: a systematic review and meta-analysis. Osong Public. Health Res Perspect. 2017;8(2):108–115. doi: 10.24171/j.phrp.2017.8.2.02.</Citation><ArticleIdList><ArticleId IdType="doi">10.24171/j.phrp.2017.8.2.02</ArticleId><ArticleId IdType="pmc">PMC5441434</ArticleId><ArticleId IdType="pubmed">28540154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang FC, Yang F, Chen L, et al. Meteorological factors affect the hand, foot, and mouth disease epidemic in Qingdao, China, 2007–2014. Epidemiol Infect. 2016;144(11):2354–2362. doi: 10.1017/S0950268816000601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816000601</ArticleId><ArticleId IdType="pmc">PMC9150528</ArticleId><ArticleId IdType="pubmed">27018924</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Wang J, Zhang C, et al. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2020;38(7):1804–1809. doi: 10.1016/j.vaccine.2019.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.12.025</ArticleId><ArticleId IdType="pubmed">31892446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Shi P, Zhou W, et al. Assessment of temperature-hand, foot, and mouth disease association and its variability across urban and rural populations in Wuxi, China: a distributed lag nonlinear analysis. Am J Trop Med Hyg. 2020;103(5):2091–2099. doi: 10.4269/ajtmh.20-0329.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0329</ArticleId><ArticleId IdType="pmc">PMC7646757</ArticleId><ArticleId IdType="pubmed">32748774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hu T, Sun D, et al. Epidemiological characteristics of hand, foot, and mouth disease in Shandong, China, 2009–2016. Sci Rep. 2017;7(1):8900. doi: 10.1038/s41598-017-09196-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09196-z</ArticleId><ArticleId IdType="pmc">PMC5567189</ArticleId><ArticleId IdType="pubmed">28827733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Fan H, Ai J, et al. Neurocognitive deficits and sequelae following severe hand, foot, and mouth disease from 2009 to 2017, in JiangSu Province, China: a long-term follow-up study. Int J Infect Dis. 2022;115:245–255. doi: 10.1016/j.ijid.2021.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.026</ArticleId><ArticleId IdType="pubmed">34910955</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Song G, He N, et al. Spatial-temporal variation and risk factor analysis of hand, foot, and mouth disease in children under 5 years old in Guangxi, China. BMC Public Health. 2019;19(1):1491. doi: 10.1186/s12889-019-7619-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-019-7619-y</ArticleId><ArticleId IdType="pmc">PMC6842152</ArticleId><ArticleId IdType="pubmed">31703735</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Zhang X, Xiao G. Spatiotemporal decomposition and risk determinants of hand, foot and mouth disease in Henan. China Sci Total Environ. 2019;657:509–516. doi: 10.1016/j.scitotenv.2018.12.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2018.12.039</ArticleId><ArticleId IdType="pubmed">30550914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BJ, Chen HJ, Chen Y, et al. The risk factors of acquiring severe hand, foot, and mouth disease: a meta-analysis. Can J Infect Dis Med Microbiol. 2018;2018:2751457. doi: 10.1155/2018/2751457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/2751457</ArticleId><ArticleId IdType="pmc">PMC6038695</ArticleId><ArticleId IdType="pubmed">30046361</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J, Lu XL, Liu X, et al. Derivation and validation of a mortality risk score for severe hand, foot and mouth disease in China. Sci Rep. 2017;7(1):3371. doi: 10.1155/2018/2751457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/2751457</ArticleId><ArticleId IdType="pmc">PMC5469765</ArticleId><ArticleId IdType="pubmed">28611398</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao J, He XY, Shi Y, et al. Epidemiology of 45,616 suspect cases of hand, foot and mouth disease in Chongqing, China, 2011–2015. Sci Rep. 2017;7:45630. doi: 10.1038/srep45630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep45630</ArticleId><ArticleId IdType="pmc">PMC5395817</ArticleId><ArticleId IdType="pubmed">28422128</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhou YH, Cheng YB, et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. Lancet Child Adolesc Health. 2019;3(10):697–704. doi: 10.1016/S2352-4642(19)30185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(19)30185-3</ArticleId><ArticleId IdType="pmc">PMC8713082</ArticleId><ArticleId IdType="pubmed">31375313</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XL, An ZJ, Huo D, et al. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing. China Hum Vaccin Immunother. 2019;15(5):1183–1190. doi: 10.1080/21645515.2019.1581539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1581539</ArticleId><ArticleId IdType="pmc">PMC6605830</ArticleId><ArticleId IdType="pubmed">30779680</ArticleId></ArticleIdList></Reference><Reference><Citation>Du ZC, Huang Y, Bloom MS, et al. Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. Hum Vaccin Immunother. 2021;17(1):217–223. doi: 10.1080/21645515.2020.1763076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1763076</ArticleId><ArticleId IdType="pmc">PMC7872061</ArticleId><ArticleId IdType="pubmed">32530733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Song J, Wang J, et al. Cost-effectiveness of a national enterovirus 71 vaccination program in China. PLoS Negl Trop Dis. 2017;11(9):e0005899. doi: 10.1371/journal.pntd.0005899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0005899</ArticleId><ArticleId IdType="pmc">PMC5608421</ArticleId><ArticleId IdType="pubmed">28892475</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang HC, Zhang Z, Rao Q, et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg Microbes Infect. 2021;10(1):619–628. doi: 10.1080/22221751.2021.1899772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1899772</ArticleId><ArticleId IdType="pmc">PMC8018479</ArticleId><ArticleId IdType="pubmed">33682641</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–488. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639–645. doi: 10.1016/j.jinf.2020.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.019</ArticleId><ArticleId IdType="pmc">PMC7118526</ArticleId><ArticleId IdType="pubmed">32240670</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>